

BIO RAD LABORATORIES INC  
 Form 4  
 September 13, 2016

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL  
 OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 HERTIA JOHN

2. Issuer Name and Ticker or Trading Symbol  
 BIO RAD LABORATORIES INC  
 [BIO, BIOB]

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)  
 \_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)  
 Executive Vice President

(Last) (First) (Middle)  
 C/O BIO-RAD LABORATORIES,  
 INC., 1000 ALFRED NOBEL  
 DRIVE  
 (Street)

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 09/09/2016

HERCULES, CA 94547

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 \_\_\_ Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | (A) or (D) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|------------|---|--|--|
|                                 |                                      |  | Code                           | V   | Amount     | Price   |  |  |
| Bio-Rad A Common Stock          | 09/09/2016                           |  | S                              |   | 2,689      | \$ 158.57<br>(1)  | 8,713  | D  |
| Bio-Rad A Common Stock          | 09/10/2016                           |  | M                              |   | 600 (2)    | \$ 0  | 9,313  | D  |
| Bio-Rad A                       | 09/11/2016                           |  | M                              |   | 1,300 (2)  | \$ 0  | 10,613   | D  |

Edgar Filing: BIO RAD LABORATORIES INC - Form 4

Common  
Stock

Bio-Rad  
A  
Common  
Stock

09/12/2016

S

728 <sup>(3)</sup> D

\$

155.0215 9,885

D

Bio-Rad  
A  
Common  
Stock

252

I

By  
Spouse

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) |                            |      |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|----------------------------|------|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title                                      | Amount or Number of Shares |      |
| Restricted Stock Units                     | \$ 0 <sup>(5)</sup>                                    | 09/10/2016                           |  | M                              | 600   | <sup>(6)</sup>   | <sup>(6)</sup>  | Bio-Rad A Common Stock                     | 600                        | \$ 0 |
| Restricted Stock Units                     | \$ 0 <sup>(5)</sup>                                    | 09/11/2016                           |  | M                              | 700   | <sup>(7)</sup>   | <sup>(7)</sup>  | Bio-Rad A Common Stock                     | 700                        | \$ 0 |
| Restricted Stock Units                     | \$ 0 <sup>(5)</sup>                                    | 09/11/2016                           |  | M                              | 600   | <sup>(8)</sup>   | <sup>(8)</sup>  | Bio-Rad A Common Stock                     | 600                        | \$ 0 |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |                          |       |
|--|---------------|-----------|--------------------------|-------|
|  | Director      | 10% Owner | Officer                  | Other |
| HERTIA JOHN<br>C/O BIO-RAD LABORATORIES, INC.<br>1000 ALFRED NOBEL DRIVE<br>HERCULES, CA 94547 |               |           | Executive Vice President |       |

## Signatures

John Hertia 09/13/2016

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$158.55 to \$158.63, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(2) Shares of Class A common stock acquired on the vesting of restricted stock units.

(3) Sold by the Issuer on behalf of the Reporting Person to satisfy certain tax obligations in connection with the vesting of restricted stock units, all in accordance with a restricted stock unit award agreement.

(4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$155.0164 to \$155.0314, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(5) Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

(6) The restricted stock units vest in five equal annual installments beginning September 10, 2015.

(7) The restricted stock units vest in five equal annual installments beginning September 11, 2014.

(8) The restricted stock units vest in five equal annual installments beginning September 11, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.